Lulizumab pegol
From Wikipedia, the free encyclopedia
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Source | Humanized |
| Target | glycoprotein CD28 |
| Clinical data | |
| Other names | BMS-931699 |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| IUPHAR/BPS | |
| ChemSpider |
|
| UNII | |
| Chemical and physical data | |
| Formula | C552H859N149O164S4 |
| Molar mass | 12335.06 g·mol−1 |
Lulizumab pegol (INN;[1] development code BMS-931699) is a monoclonal antibody developed by Bristol-Myers Squibb for the treatment of autoimmune diseases[2] such as cutaneous lupus erythematosus.[3]
